vs
太平洋生物科学（ASMB）与RYTHM, Inc.（RYM）财务数据对比。点击上方公司名可切换其他公司
太平洋生物科学的季度营收约是RYTHM, Inc.的1.0倍（$10.8M vs $10.7M），太平洋生物科学净利率更高（-85.2% vs -127.6%，领先42.4%），RYTHM, Inc.同比增速更快（242.0% vs 57.6%）
该公司是一家成立于2004年的美国生物科技企业，主要研发生产基因测序相关设备，同时也开展新型实时生物观测技术相关业务。目前拥有两大核心测序平台，分别是基于零模波导特性的单分子实时测序平台，以及结合天然核苷酸无痕连接技术的结合测序平台。
RYTHM Inc.是一家临床阶段生物制药企业，专注于研发和商业化针对罕见遗传性内分泌与代谢疾病的创新疗法，主要面向美国市场，服务存在未被满足医疗需求的儿童及成人患者群体。
ASMB vs RYM — 直观对比
营收规模更大
ASMB
是对方的1.0倍
$10.7M
营收增速更快
RYM
高出184.4%
57.6%
净利率更高
ASMB
高出42.4%
-127.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.8M | $10.7M |
| 净利润 | $-9.2M | $-13.6M |
| 毛利率 | — | 75.5% |
| 营业利润率 | -100.9% | -121.5% |
| 净利率 | -85.2% | -127.6% |
| 营收同比 | 57.6% | 242.0% |
| 净利润同比 | 4.3% | 44.1% |
| 每股收益（稀释后） | $-0.72 | $-6.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMBRYM
| Q4 25 | — | $10.7M | ||
| Q3 25 | $10.8M | $4.0M | ||
| Q2 25 | $9.6M | $2.0M | ||
| Q1 25 | $9.4M | $538.0K | ||
| Q4 24 | $7.4M | $-7.5M | ||
| Q3 24 | $6.8M | $1.9M | ||
| Q2 24 | $8.5M | $3.0M | ||
| Q1 24 | $5.8M | $2.6M |
净利润ASMBRYM
| Q4 25 | — | $-13.6M | ||
| Q3 25 | $-9.2M | $-10.7M | ||
| Q2 25 | $-10.2M | $-7.4M | ||
| Q1 25 | $-8.8M | $-1.6M | ||
| Q4 24 | — | $-24.4M | ||
| Q3 24 | $-9.6M | $-18.7M | ||
| Q2 24 | $-11.2M | $-3.0M | ||
| Q1 24 | $-9.1M | $4.2M |
毛利率ASMBRYM
| Q4 25 | — | 75.5% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 16.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 11.6% | ||
| Q2 24 | — | 37.6% | ||
| Q1 24 | — | 6.4% |
营业利润率ASMBRYM
| Q4 25 | — | -121.5% | ||
| Q3 25 | -100.9% | -219.8% | ||
| Q2 25 | -115.2% | -332.9% | ||
| Q1 25 | -105.5% | -687.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -160.1% | -63.1% | ||
| Q2 24 | -143.0% | -28.5% | ||
| Q1 24 | -185.5% | 13.6% |
净利率ASMBRYM
| Q4 25 | — | -127.6% | ||
| Q3 25 | -85.2% | -263.8% | ||
| Q2 25 | -105.9% | -360.4% | ||
| Q1 25 | -93.6% | -302.2% | ||
| Q4 24 | — | 324.4% | ||
| Q3 24 | -140.4% | -964.4% | ||
| Q2 24 | -130.7% | -99.3% | ||
| Q1 24 | -156.9% | 163.0% |
每股收益（稀释后）ASMBRYM
| Q4 25 | — | $-6.78 | ||
| Q3 25 | $-0.72 | $-5.33 | ||
| Q2 25 | $-1.33 | $-3.74 | ||
| Q1 25 | $-1.17 | $-0.83 | ||
| Q4 24 | — | $-24.26 | ||
| Q3 24 | $-1.51 | $-17.28 | ||
| Q2 24 | $-1.98 | $-3.16 | ||
| Q1 24 | $-1.66 | $3.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.5M | $32.2M |
| 总债务越低越好 | — | $80.6M |
| 股东权益账面价值 | $182.7M | $13.0M |
| 总资产 | $240.0M | $106.7M |
| 负债/权益比越低杠杆越低 | — | 6.19× |
8季度趋势，按日历期对齐
现金及短期投资ASMBRYM
| Q4 25 | — | $32.2M | ||
| Q3 25 | $22.5M | — | ||
| Q2 25 | $24.0M | $41.0M | ||
| Q1 25 | $23.4M | $24.4M | ||
| Q4 24 | $38.3M | — | ||
| Q3 24 | $28.5M | $267.0K | ||
| Q2 24 | $19.2M | $57.0K | ||
| Q1 24 | $18.7M | $99.0K |
总债务ASMBRYM
| Q4 25 | — | $80.6M | ||
| Q3 25 | — | $90.6M | ||
| Q2 25 | — | $40.6M | ||
| Q1 25 | — | $10.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $4.6M | ||
| Q1 24 | — | — |
股东权益ASMBRYM
| Q4 25 | — | $13.0M | ||
| Q3 25 | $182.7M | $11.7M | ||
| Q2 25 | $18.1M | $21.0M | ||
| Q1 25 | $27.1M | $26.8M | ||
| Q4 24 | $33.4M | $28.1M | ||
| Q3 24 | $26.0M | $5.5M | ||
| Q2 24 | $34.7M | $8.5M | ||
| Q1 24 | $32.6M | $-5.5M |
总资产ASMBRYM
| Q4 25 | — | $106.7M | ||
| Q3 25 | $240.0M | $115.2M | ||
| Q2 25 | $80.8M | $69.5M | ||
| Q1 25 | $99.0M | $45.6M | ||
| Q4 24 | $119.2M | $54.0M | ||
| Q3 24 | $100.3M | $39.0M | ||
| Q2 24 | $115.3M | $39.4M | ||
| Q1 24 | $119.9M | $40.6M |
负债/权益比ASMBRYM
| Q4 25 | — | 6.19× | ||
| Q3 25 | — | 7.73× | ||
| Q2 25 | — | 1.94× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.13× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.1M | $-3.0M |
| 自由现金流经营现金流 - 资本支出 | $-15.2M | — |
| 自由现金流率自由现金流/营收 | -140.7% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASMBRYM
| Q4 25 | — | $-3.0M | ||
| Q3 25 | $-15.1M | $-5.4M | ||
| Q2 25 | $-16.8M | $-8.4M | ||
| Q1 25 | $-23.4M | $-6.7M | ||
| Q4 24 | $-51.1M | $-5.3M | ||
| Q3 24 | $-15.2M | $-1.4M | ||
| Q2 24 | $-17.1M | $-1.8M | ||
| Q1 24 | $-18.4M | $-3.0M |
自由现金流ASMBRYM
| Q4 25 | — | — | ||
| Q3 25 | $-15.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-51.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-17.1M | $-1.8M | ||
| Q1 24 | $-18.4M | $-3.0M |
自由现金流率ASMBRYM
| Q4 25 | — | — | ||
| Q3 25 | -140.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -695.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -200.6% | -61.2% | ||
| Q1 24 | -317.7% | -115.1% |
资本支出强度ASMBRYM
| Q4 25 | — | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.2% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率ASMBRYM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASMB
暂无分部数据
RYM
| Nonlicensing Revenue | $9.5M | 89% |
| Cultivation Business Discontinued Operations | $1.2M | 11% |
